Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.

The platform can process millions of samples per day, assessing and isolating rare or valuable cell variants or biological products, to simplify and improve throughput across antibody discovery, cell line development and single cell diagnostics. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers.

Sphere Fluidics Closes A $40 Million Funding Round Led By Sofinnova Partners And Redmile Group

Description

Company Information

Funding Insights

Sphere Fluidics Closes A $40 Million Funding Round Led By Sofinnova Partners And Redmile Group

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information